Completed PHASE2 INTERVENTIONAL 1-arm NCT00005906

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Ascites Lymphangioleiomyomatosis Lymphangiomyomas Pleural Effusions

Interventions Octreotide

Updated 5 times since 2017 Last updated: Apr 29, 2010 Started: Jun 30, 2000 Primary completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00005906, this PHASE2 trial focuses on Ascites and Lymphangioleiomyomatosis and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 5 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States